N/A Helicobacter Pylori Infection
Conditions
Interventions
day dual therapy containing 500 mg amoxicillin 4 times daily and 20 mg vonoprazan twice daily ,14-
day triple therapy containing 1 g amoxicillin twice daily,
1 g clarithromycin MR once daily,
and 20 mg vonoprazan twice daily
Active Comparator Drug,Active Comparator Drug
vonoprazan-
based dual therapy,vonoprazan-
based triple therapy
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Thai patients with the age between 18 and 75 years Detecting for H.pylori infection with positive urease test and/or pathological findings of H.pylori and/or positive
Exclusion criteria
Exclusion criteria: Any cases with upper gastrointestinal bleeding Being treated with medications affecting the research outcome, for example, by using antibiotics including amoxicillin, clarithromycin, metronidazole or fluoroquinolone within 1 month before the enrollment. Contraindicated for gastric biopsy such as coagulopathy. Any history of drug allergy for amoxicillin, clarithromycin or vonoprazan. Receiving proton pump inhibitor within 4 weeks or receiving any antibiotics or bismuth within 2 weeks. Being pregnant or raising children with lactation. Having history of H.pylori eradication treatment. Having severe underlying disease including end-stage renal disease requiring hemodialysis or peritoneal dialysis (GFR < 15), cirrhosis with Child-Pugh classification grade C, immunocompromised host with AIDS, malignancy and/or bed ridden cerebrovascular disease. Any cases who receiving anticoagulant. Having previous gastric surgery. Unwilling to participate into research. Having history of taking previous medications which interacted with the research treatment. Having underlying heart disease including congenital long QT syndrome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eradication rate of Helicobacter pylori infection 4 weeks after last dose eradication rate of 14-day vonoprazan-based dual therapy and 14-day vonoprazan-based triple therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effect ุุ6 month To measure the adverse effect reaction of 14-day vonoprazan-based dual therapy and 14-day vonoprazan | — |
Countries
Thailand
Contacts
Public ContactLikhasit Sanglutong
Thammasat University Hospital
Outcome results
None listed